BP-1-102 and silencing of Fascin-1 by RNA interference inhibits the proliferation of mouse pituitary adenoma AtT20 cells via the signal transducer and activator of transcription 3/fascin-1 pathway

References

• Kopczak A, Renner U, Karl SG. Advances in understanding pituitary tumors. F1000 Prime Rep. 2014;6(2):5.
   PubMedGoogle Scholar
• Chatzellis E, Alexandraki KI, Androulakis I, et al. Aggressive pituitary tumors. Neuroendocrinology. 2015;101(2):87–104.
   PubMed Web of Science ®Google Scholar
• Darnell J, Kerr I, Stark G. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421.
   PubMed Web of Science ®Google Scholar
• Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 2007;13(5):1362–1366.
   PubMed Web of Science ®Google Scholar
• Huang C, Cao J, Huang KJ, et al. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci. 2006;97(12):1417–1423.
   PubMed Web of Science ®Google Scholar
• Wake MS, Watson CJ. STAT3 the oncogene-Still eluding therapy? FEBS J. 2015;282(14):2600–2611.
   PubMed Web of Science ®Google Scholar
• Sun J, He H, Xiong Y, et al. Fascin protein is critical for transforming growth factor beta protein-induced invasion and filopodia formation in spindle-shaped tumor cells. J Biol Chem. 2011;286(45):38865–38875.
   PubMed Web of Science ®Google Scholar
• Bryan J, Kane RE. Separation and interaction of the major components of sea urchin actin gel. J Mol Biol. 1978;125(2):207–224.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Skacel M, Adams JC. Roles of Fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol. 2005;37(9):0–1804.
   Web of Science ®Google Scholar
• Tan VY, Lewis SJ, Adams JC, et al. Association of Fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013;11(1):52.
   PubMedGoogle Scholar
• Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. Hepatology. 2009;50(6):2007–2013.
   PubMed Web of Science ®Google Scholar
• Acloque H, Adams MS, Fishwick K, et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119(6):1438–1449.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–142.
   PubMed Web of Science ®Google Scholar
• Noh MG, Oh SJ, Ahn EJ, et al. Prognostic significance of E-cadherin and N-cadherin expression in Gliomas. BMC Cancer. 2017;17(1):583–586.
   PubMedGoogle Scholar
• Kokkinos MI, Wafai R, Wong MK, et al. Vimentin and epithelial-mesenchymal transition in human breast cancer–observations in vitro and in vivo. Cells Tissues Organs. 2007;185(1–3):191–203.
   PubMed Web of Science ®Google Scholar
• Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15(2):117–134.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516–524.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Régis J, Dufour H, et al. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol. 2010;6(4):214–223.
   PubMed Web of Science ®Google Scholar
• Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002;2(10):740–749.
   PubMed Web of Science ®Google Scholar
• Wang X, Crowe PJ, Goldstein D, et al. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers. Int J Oncol. 2012;41(4):1181–1191.
   PubMed Web of Science ®Google Scholar
• Snyder M, Huang XY, Zhang J. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem. 2011;286(45):38886–38893.
   PubMed Web of Science ®Google Scholar
• Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13(2):211–217.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138(11):2570–2578.
   PubMed Web of Science ®Google Scholar
• Hu FY, Wang LP, Hou LL, et al. The expressions of STAT3, WWOX and c-myc in human non-small cell lung cancer tissue and correlativity analysis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010;26:1203–1205.
   PubMedGoogle Scholar
• Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer. 2015;14(1):100.
   PubMedGoogle Scholar
• Liu J, Liang L, Li D, et al. JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‑cell lymphoma, nasal type. Oncol Rep. 2019;41:3219–3232.
   PubMed Web of Science ®Google Scholar
• Rokavec M, Öner MG, Li H, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124(4):1853–1867.
   PubMed Web of Science ®Google Scholar
• Zhou C, Jiao Y, Wang R, et al. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest. 2015;125(4):1692–1702.
   PubMed Web of Science ®Google Scholar
• Feng J, Yu SY, Li CZ, et al. Integrative proteomics and transcriptomics revealed that activation of the IL-6R/JAK2/STAT3/MMP9 signaling pathway is correlated with invasion of pituitary null cell adenomas. Mol Cell Endocrinol. 2016;436:195–203.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Z, Li R, et al. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway. Biomed Pharmacother. 2018;97:1066–1077.
   PubMed Web of Science ®Google Scholar
• Expression and significance of E-cadherin, N-cadherin, transforming growth factor-β1 and Twist in prostate cancer. Asian Pac J Trop Med. 2014;7(1):76–82.
   PubMed Web of Science ®Google Scholar
• Zhou K, Jin H, Luo Y. Expression and significance of E-cadherin and? -catenins in pituitary adenoma. Int J Surg Pathol. 2013;21(4):363–367.
   PubMed Web of Science ®Google Scholar
• Tong D, Liu Q, Liu G, et al. Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. Cancer Lett. 2017;389:23–32.
   PubMed Web of Science ®Google Scholar
• Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (stat3) protein. J Med Chem. 2012;55(15):6645–6668.
   PubMed Web of Science ®Google Scholar
• Deng J, Grande F, Neamati N. Small molecule inhibitors of stat3 signaling pathway.Curr Cancer Drug Targets. 2007;7(1):91–107.
   PubMed Web of Science ®Google Scholar
• Xiong A, Yang Z, Shen Y, et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers. 2014;6(2):926–957.
   PubMed Web of Science ®Google Scholar
• Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Exp Opin Ther Patent. 2011;21(1):65–83.
   PubMed Web of Science ®Google Scholar
• Finerty PJ, Mittermaier AK, Muhandiram R, et al. NMR dynamics-derived insights into the binding properties of a peptide interacting with an SH2 domain. Biochemistry. 2005;44(2):694–703.
   PubMed Web of Science ®Google Scholar
• Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 2007;104(18):7391–7396.
   PubMed Web of Science ®Google Scholar
• Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene. 2009;28(7):961–972.
   PubMed Web of Science ®Google Scholar
• Shahani VM, Yue P, Haftchenary S, et al. Identification of purine-scaffold small-molecule inhibitors of stat3 activation by QSAR studies. ACS Med Chem Lett. 2011;2(1):79–84.
   PubMed Web of Science ®Google Scholar
• Li L, Brian H, Pui-Kai L, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 2010;12(1):39–IN5–50.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun Y, Pireddu R, et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 2013;73(6):1922–1933.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yue P, Page BDG, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci. 2012;109(24):9623–9628.
   PubMed Web of Science ®Google Scholar
• Jiang X, Tang J, Wu M, et al. BP‑1‑102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways. Mol Med Rep. 2019;19:2698–2706.
   PubMed Web of Science ®Google Scholar
• Adams JC. Roles of Fascin in cell adhesion and motility. Curr Opin Cell Biol. 2004;16(5):590–596.
   PubMed Web of Science ®Google Scholar
• Otto J, Kane RE, Bryan J. Formation of filopodia in coelomocytes: localization of fascin, a 58,000 dalton actin cross-linking protein. Cell. 1979;17(2):285–293.
   PubMed Web of Science ®Google Scholar
• Bryan J, Edwards R, Matsudaira P, et al. Fascin, an echinoid actin-bundling protein, is a homolog of the drosophila singed gene product.Proc Natl Acad Sci USA . 1993;90(19):9115–9119.
   PubMed Web of Science ®Google Scholar
• Zhang FR, Tao LH, Shen ZY, et al. Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem. 2011;59(11):1001–1008.
   PubMed Web of Science ®Google Scholar
• Tubb BE, Bardien-Kruger S, Kashork CD, et al. Characterization of human retinal Fascin gene (FSCN2) at 17q25: close physical linkage of Fascin and cytoplasmic actin genes. Genomics. 2000;65(2):146–156.
   PubMed Web of Science ®Google Scholar
• Tubb B, Mulholland DJ, Vogl W, et al. Testis Fascin (FSCN3): a novel paralog of the actin-bundling protein Fascin expressed specifically in the elongate spermatid head. Exp Cell Res. 2002;275(1):92–109.
   PubMed Web of Science ®Google Scholar
• Gao W, Zhang C, Feng Y, et al. Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma. PLoS One. 2012;7(11):e50710.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Skacel M, Lavery IC, et al. Prognostic significance of Fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2011;11(1):488.
   Google Scholar
• Li X, Zheng H, Hara T, et al. Aberrant expression of cortactin and Fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Int J Oncol. 2008;33(1):69–79.
   PubMed Web of Science ®Google Scholar
• Jin LH, Jung AH, Hoen KT, et al. Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients. J Cancer. 2017;8(16):3122–3129.
   PubMed Web of Science ®Google Scholar
• Zou J, Yang H, Chen F, et al. Prognostic significance of Fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prevent. 2010;19(1):11–17.
   PubMed Web of Science ®Google Scholar
• Liang Z, Wang Y, Shen Z, et al. Fascin-1 promoted the growth and migration of non-small cell lung cancer cells by acti vating YAP/TEAD signaling. Tumor Biol. 2016;37(8):10909–10915.
   PubMedGoogle Scholar
• Hashimoto Y, Kim DJ, Adams JC. The roles of fascins in health and disease. J Pathol. 2011;224(3):289–300.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Osanai M, Lee GH. Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases. Cancer Sci. 2011;102(6):1228–1235.
   PubMed Web of Science ®Google Scholar
• Liu C, Li C, Li D, et al. role of FSCN1 in migration and invasion of pituitary adenomas. Mol Cell Endocrinol. 2016;419:217–224.
   PubMed Web of Science ®Google Scholar
• Chen L. MicroRNA133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting Fascin actinbundling protein 1. FASEB J. 2001;15(1):25–27.
   PubMedGoogle Scholar
• Ortiz CM, Ito T, Hashimoto Y, et al. Effects of small interfering RNAs targeting Fascin on human esophageal squamous cell carcinoma cell lines. Diagn Pathol. 2010;5(1):41.
   PubMedGoogle Scholar
• Snyder M, Huang J, Huang XY, et al. A signal transducer and activator of transcription 3·nuclear factor κB (Stat3·NFκB) complex is necessary for the expression of fascin in metastatic breast cancer cells in response to interleukin (IL)-6 and tumor necrosis factor (TNF)-α. J Biol Chem. 2014;289(43):30082–30089.
   PubMed Web of Science ®Google Scholar
• Yao J, Qian C, Bei YE, et al. Signal transducer and activator of transcription 3 signaling upregulates Fascin via nuclear factor-κB in gastric cancer: implications in cell invasion and migration. Oncol Lett. 2014;7(3):902–908.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhao Q, Cai Z, et al. Fas signaling promotes gastric cancer metastasis through STAT3-dependent upregulation of fascin. PLoS One. 2015;10(5):e0125132.
   PubMed Web of Science ®Google Scholar
• Park KS, Yoon SY, Park SH, et al. Anti-migration and anti-invasion effects of curcumin via suppression of fascin expression in glioblastoma cells. Brain Tumor Res Treat. 2019;7(1):16–24.
   PubMedGoogle Scholar
• Roy FV, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756–3788.
   PubMed Web of Science ®Google Scholar
• Kourtidis A, Lu R, Pence LJ, et al. A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358(1):78–85.
   PubMed Web of Science ®Google Scholar
• Lombaerts M, Van Wezel T, Philippo K, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer. 2006;94(5):661–671.
   PubMed Web of Science ®Google Scholar
• Berx G, Van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspect Biol. 2009;1(6):a003129–a003129.
   PubMed Web of Science ®Google Scholar
• Ko HS, Choi SK, Kang HK, et al. Oncostatin M stimulates cell migration and proliferation by down-regulating E-cadherin in HTR8/SVneo cell line through STAT3 activation. Reprod Biol Endocrinol. 2013;11(1):93–93.
   PubMedGoogle Scholar
• Kong G, Jiang Y, Sun X, et al. Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway. Oncol Rep. 2017;38(5):2647–2656.
   PubMed Web of Science ®Google Scholar